Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement

Ling Yu, Jietao Lin, Hanhan Li, Lingling Sun, Shubo Wang, Yaoxu Chen, Hanrui Chen, Lin LizhuFrontiers in Pharmacology 2023 · DOI

Abstract

Cancer of unknown primary (CUP) represents a challenging subset of metastatic tumors where the primary site cannot be identified using standard diagnostic protocols. This case report describes an 80-year-old female patient with CUP who achieved significant clinical benefit from a sequence of targeted therapies. Initially treated with the multi-target tyrosine kinase inhibitor (TKI) anlotinib, the patient maintained stable disease (SD) for two years. Upon progression, next-generation sequencing (NGS) identified a novel BRCA1 large genomic rearrangement (LGR)—an exon 17-18 inversion. Subsequent treatment with the PARP inhibitor olaparib and the immunotherapy pembrolizumab resulted in an additional six months of stable disease. This case highlights the potential of precision oncology and "chemo-free" regimens in managing CUP.

Introduction

Cancer of Unknown Primary (CUP) accounts for approximately 3%–5% of all new cancer diagnoses annually. By definition, these are histologically confirmed metastatic malignancies for which the primary anatomical site remains elusive despite comprehensive diagnostic workups. Due to the lack of a primary site to guide standard-of-care protocols, most CUP patients receive empiric, broad-spectrum chemotherapy. However, the prognosis remains poor, with median survival typically ranging from 6 to 10 months.

The advent of precision medicine and next-generation sequencing (NGS) offers a paradigm shift. By identifying actionable genomic alterations, clinicians can move toward site-agnostic, biomarker-driven therapies, potentially improving outcomes for this difficult-to-treat population.

Case Presentation

An 80-year-old woman presented with abdominal masses and ascites. Initial imaging and immunohistochemical (IHC) evaluations were performed to locate a primary tumor, but results were inconclusive, ruling out common origins such as the breast, ovaries, or gastrointestinal tract.

CT scan of the abdomen showing the initial presentation of masses.
Histological analysis of the metastatic tumor tissue confirming the diagnosis of CUP.

The patient declined traditional chemotherapy. Given her age and preference, a "chemo-free" approach was initiated. Starting in February 2019, she received anlotinib, a multi-target TKI that inhibits VEGFR, FGFR, and PDGFR. This treatment successfully stabilized the disease for 24 months, a duration significantly exceeding the average survival for CUP.

Genomic Profiling and Precision Therapy

Following disease progression after two years on anlotinib, the clinical team performed comprehensive genomic profiling using a 733-gene NGS panel on an ascites sample. The analysis revealed a novel somatic BRCA1 large genomic rearrangement (LGR): an inversion involving exons 17 and 18. While BRCA1 deletions and duplications are well-documented, this specific inversion had not been previously reported in medical literature.

Additionally, the tumor exhibited a high tumor mutation burden (TMB-H). Based on these findings, the treatment regimen was pivoted to include olaparib, a PARP inhibitor targeting the DNA repair deficiency caused by the BRCA1 mutation, and pembrolizumab, an anti-PD-1 immunotherapy. This targeted combination resulted in another period of stable disease lasting over six months, with the patient's condition remaining stable at the time of the report.

Discussion

This case underscores several critical insights for the management of CUP. First, it demonstrates that multi-target TKIs like anlotinib can provide long-term disease control as a first-line therapy, especially in elderly patients who may not tolerate or desire cytotoxic chemotherapy.

Second, the discovery of the BRCA1 exon 17-18 inversion expands our understanding of genomic instability in CUP. Large genomic rearrangements are often missed by standard sequencing techniques but can be identified through comprehensive NGS panels. The clinical response to olaparib suggests that this novel inversion is a functional driver of homologous recombination deficiency (HRD), rendering the tumor susceptible to PARP inhibition.

Conclusion

For patients with Cancer of Unknown Primary, a biomarker-driven approach can significantly extend survival beyond the limitations of empiric chemotherapy. This case report highlights the importance of comprehensive genomic profiling in identifying rare, actionable mutations like BRCA1 LGRs. A "chemo-free" regimen consisting of TKIs and PARP inhibitors represents a viable and effective strategy for precision management of site-agnostic cancers.

Summary updated

Abstract

<b>Background</b>: Cancer of unknown primary (CUP), which accounts for 3%-5% of new cancer cases every year, involves the presence of a type of histologically confirmed metastatic tumors whose primary site cannot be confirmed by conventional diagnostic methods. This difficulty in identifying the primary site means that CUP patients fail to receive precisely targeted therapy. Most patients are treated with empiric chemotherapy, with a median survival of 6 months and even poorer prognosis within an unfavorable subset of CUP. <b>Case report:</b> An 80-year-old woman presented with masses in the abdomen. Following comprehensive imagological and immunohistochemical examinations, she was diagnosed with CUP. She emphatically declined chemotherapy; thus, anlotinib has been administered with patient consent since 02/07/2019, and stable disease (SD) was observed for 2 years. During subsequent treatment, a large genomic rearrangement in <i>BRCA1</i> was identified in the patient <i>via</i> NGS, and SD was observed for a further 6 months following olaparib treatment. The type of LGR identified in this patient was discovered to be <i>BRCA1</i> exon 17-18 inversion (inv), which has never been previously reported. <b>Conclusion:</b> For CUP patients, a chemo-free regimen seems to be acceptable as a first-line treatment, and NGS-guided targeted treatment could improve patient outcomes.
BibTeX
@inproceedings{yu2023case,
  author = {Ling Yu and Jietao Lin and Hanhan Li and Lingling Sun and Shubo Wang and Yaoxu Chen and Hanrui Chen and Lin Lizhu},
  title = {{Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement}},
  booktitle = {Frontiers in Pharmacology},
  year = {2023},
  doi = {10.3389/fphar.2023.997760},
}
Figure